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ELECTROPHYSIOLOGY
Is Hospital Admission for Initiation of Antiarrhythmic Therapy With
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Yield of In-Hospital Monitoring and Prediction of Risk for Significant
Arrhythmia Complications
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VICTOR A. MORANT, MD, FACC, DAVE P. MILLER, MS,* PATRICK J. TCHOU, MD, FACC
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Objectives. We sought to determine the yield of in-hospital
monitoring for detection of significant arrhythmia complications
in patients starting sotalol therapy for atrial arrhythmias and to
identify factors that might predict safe outpatient initiation.
Background. The need for hospital admission during initiation
of antiarrhythmic therapy has been questioned, particularly for
sotalol, with which proarrhythmia may be dose related.
Methods. The records of 120 patients admitted to the hospital
for initiation of sotalol therapy were retrospectively reviewed to
determine the incidence of significant arrhythmia complications,
defined as new or increased ventricular arrhythmias, significant
bradycardia or excessive corrected QT (QTc) interval prolonga-
tion.
Results. Twenty-five patients (20.8%) experienced 35 complica-
tions, triggering therapy changes during the hospital period in 21
(17.5%). New or increased ventricular arrhythmias developed in 7
patients (5.8%) (torsade de pointes in 2), significant bradycardia
in 20 (16.7%) (rate <40 beats/min in 13, pause >3.0 s in 4,
third-degree atrioventricular block in 1, permanent pacemaker
implantation in 3) and excessively prolonged QTc intervals in 8
(6.7%) (dosage reduced or discontinued in 6). Time to the earliest
detection of complications was 2.1 6 2.5 (mean 6 SD) days after
initiation of sotalol, with 22 of 25 patients meeting criteria for
complications within 3 days of monitoring. Baseline electrocar-
diographic intervals or absence of heart disease failed to distin-
guish a low risk group. Multivariate analysis identified absence of
a pacemaker as the only significant predictor of arrhythmia
complications (p 5 0.022).
Conclusions. Because clinically significant complications can
be detected with in-hospital monitoring in one of five patients
starting sotalol therapy, hospital admission is warranted for
initiation of sotalol. Patients without pacemakers are at higher
risk for these complications.
(J Am Coll Cardiol 1998;32:169–76)
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Hospital admission for monitoring during the initiation of
primary antiarrhythmic drugs for atrial fibrillation remains
controversial, particularly with sotalol. The risk of proarrhyth-
mia from class I drugs has been reported to range from 1% to
8% (1–4). For sotalol, a class III potassium channel blocking
agent that causes QT interval prolongation, this risk is 2% to
8% (5–8). In contrast to class IA antiarrhythmic agents, such
as quinidine, with which proarrhythmia may be idiosyncratic
(2,3,9–11), the proarrhythmia associated with sotalol may be
more dose dependent (12,13), with risk potentially related
to and detectable by monitoring of QT interval prolonga-
tion. As attention to health care cost containment and
minimization of hospital lengths of stay has increased, the
need for in-hospital initiation of sotalol has been ques-
tioned. However, sotalol does have the potential to cause
significant life-threatening proarrhythmia, including signifi-
cant bradycardia, which can enhance the risk of torsade de
pointes, particularly in view of the reverse use dependence
properties of sotalol (14,15).
In the current study we sought to determine 1) the yield of
in-hospital monitoring for the detection of significant arrhyth-
mias that could result in the need for intervention or dosage
modification during the initiation of sotalol; and 2) whether
baseline clinical, electrocardiographic (ECG) or echocardio-
graphic characteristics could be used to predict which patients
would be at particularly high risk for significant arrhythmia
complications that would justify hospital admission and in
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which patients sotalol therapy might be safely initiated on an
outpatient basis.
Methods
Patients. The hospital records of patients treated with
sotalol at The Cleveland Clinic Foundation during the period
from April 1993 through December 1993 were retrospectively
reviewed. From pharmacy records, oral sotalol was dispensed
to 174 patients during the study period. During the time period
of the study, it was the policy of the cardiac electrophysiology
section to initiate sotalol therapy in all patients in the hospital
during telemetry with continuous recording. Record review
identified 120 patients who received the drug for the first time
for treatment of atrial arrhythmias during the index hospital
period. These patients represented the focus of the present
study. Patients were excluded from the study if sotalol was
initiated primarily for the treatment of ventricular arrhythmias
(n 5 38), or if they had previously received sotalol (n 5 13).
Chart review revealed three patients who were not actually
receiving sotalol. Baseline demographic, clinical, ECG and
echocardiographic variables were collected. The incidence of
significant arrhythmia complications and subsequent changes
in therapies were determined from review of hospital records,
including vital signs, telemetry or 24-h Holter monitoring and
all ECGs. Telephone or chart follow-up, or both, was per-
formed in all 104 patients discharged with sotalol (mean
follow-up 7.8 months, range 4 days to 16.9 months).
Definitions. Atrial arrhythmias were defined as chronic if
they were persistent and present for $2 months before admis-
sion. Arrhythmias were classified as paroxysmal if they were
intermittent or, if present on admission, had been sustained for
,2 months before the index hospital admission. ECG intervals
were determined using computer-generated measurements
(Marquette Electronics, Inc.) and reviewed for accuracy by the
investigators. The corrected QT interval (QTc) was calculated
using the Bazett formula (QT interval)/(RR interval)1/2 (16).
Significant arrhythmia complications were defined as 1) new or
increased ventricular arrhythmias (new or increased ventricu-
lar ectopic beats or ventricular tachycardia, including torsade
de pointes), as determined by the primary physicians caring for
the patients; 2) significant bradycardia (heart rate #40 beats/
min, pause $3.0 s, or resulting in pacemaker implantation or
dose reduction); or 3) excessive QTc interval prolongation
(.25% from baseline). Patients categorized as having no
significant heart disease had no significant coronary or valvular
disease or myocardial dysfunction. Patients with left ventricu-
lar hypertrophy by echocardiography or hypertension were not
excluded from this category.
Statistical analysis. Statistical analysis was performed to
determine univariate and multivariate baseline demographic,
clinical, ECG and echocardiographic predictors of significant
arrhythmia complications occurring before discharge from the
hospital. Results are reported as mean value 6 SD, unless
otherwise stated. Continuous variables were compared using
two-tailed Student t tests. Categoric variables were analyzed
using chi-square or Fisher exact tests. Multiple logistic regres-
sion models, including stepwise methods, were used to mea-
sure associations between predictors and outcomes while
adjusting for other variables (SPSS, Inc. and SAS). Differences
were considered significant at p , 0.05.
Results
Patient characteristics. One hundred twenty patients were
admitted to the hospital for initiation of sotalol therapy for
atrial arrhythmias (mean age 64 years; 64% male) (Table 1).
Approximately 80% had underlying heart disease, and 20%
had no heart disease. Of 117 patients (97.5%) with atrial
fibrillation or atrial flutter, or both, 31 had both atrial fibrilla-
tion and flutter, and 11 had atrial fibrillation and other
supraventricular arrhythmias, including atrial tachycardias.
The three remaining patients had no history of atrial fibrilla-
tion and were treated for atrial tachycardia. Arrhythmias were
paroxysmal in 84% of patients. The mean number of previously
failed Vaughan Williams class I or III antiarrhythmic drugs was
1.93 (range 0 to 6). Twelve patients had a previous history of
sustained ventricular tachycardia or ventricular fibrillation.
Two patients had a history of proarrhythmia, both in response
to class IC antiarrhythmic agents. None had a previous history
of torsade de pointes. Permanent pacemakers had been im-
planted in 31 patients before initiation of sotalol therapy. The
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
ICD 5 implantable cardioverter-defibrillator
Table 1. Clinical Characteristics of 120 Study Patients
Age (yr) 63.8 6 11.9
Male 77 (64%)
No significant heart disease 24 (20%)
Underlying heart disease 96 (80%)
CAD 51 (43%)
Valvular disease 56 (47%)
Atrial arrhythmia
Atrial fibrillation 114 (95%)
Atrial flutter 34 (28%)
Other supraventricular arrhythmia 14 (12%)
Paroxysmal/chronic 101 (84%)/19 (16%)
Mean no. previously failed AADs 1.93 6 1.29
Previous ventricular arrhythmia
NSVT 7 (6%)
SMVT/VF 12 (10%)
SMVT 6 (5%)
Proarrhythmia 2 (2%)
Previous permanent pacemaker 31 (26%)
Data presented are mean value 6 SD or number (%) of patients. AADs 5
antiarrhythmic drugs; CAD 5 coronary artery disease; NSVT 5 nonsustained
ventricular tachycardia; SMVT 5 sustained monomorphic ventricular tachycar-
dia; VF 5 ventricular fibrillation.
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starting dose of sotalol was 192.0 6 58.1 mg/day (median dose
160, range 80 to 320). The rhythm at initiation of sotalol was
atrial fibrillation in 68 patients.
Significant arrhythmia complications. Significant arrhyth-
mia complications were detected in 25 patients (20.8%) who
experienced a total of 35 end points (Table 2). Seven patients
(5.8%) developed new or increased ventricular arrhythmias, 8
(6.7%) developed excessively prolonged QT intervals, and 20
(16.7%) developed significant bradycardia. The clinical recog-
nition of significant arrhythmia complications prompted a
change in therapy during the hospital period in 21 patients
(17.5%). Pacemakers were implanted in 3 patients (2.5%);
sotalol was discontinued in 5 (4.2%); sotalol dosage was
reduced in 18 (15.0%); and potassium was repleted in 1
(0.8%).
Prolonged QTc interval. Of the eight patients with a
prolonged QTc interval, all except two had either concomitant
bradycardia (three patients), new or increased ventricular
arrhythmias (two patients) or bradycardia and new or in-
creased ventricular arrhythmias (one patient). The remaining
two patients had prolongation of the QTc interval to 606 and
656 ms, with the latter having bradycardia to 45 beats/min and
hypotension that triggered discontinuation of sotalol. Sotalol
dosage was reduced in four patients and discontinued in two.
Potassium was repleted in one patient. The maximal QTc
interval in the patients who developed a QTc interval .25%
from baseline ranged from 544 to 656 ms.
Bradycardia. Significant bradycardia occurred in 20 pa-
tients (16.7%) (Table 2). Fourteen patients (11.7%) had
minimal heart rates #40 beats/min, and 5 (4.2%) had pauses
$3.0 s. Six patients (5.0%) had minimal heart rates #35
beats/min. One patient had marked bradycardia requiring
temporary pacing before electrical cardioversion. After cardio-
version he developed complete atrioventricular block and
subsequently underwent permanent pacemaker implantation.
Three patients developed pauses .3.0 s after spontaneous
cardioversion to sinus rhythm from atrial fibrillation, and three
developed bradycardia to heart rates #40 beats/min after
cardioversion. One patient had sinus arrest for 30 s after
electrical cardioversion that was treated with atropine. Ther-
apy changes were prompted in 18 patients (15.0%), with
dosage reductions in 16 and permanent pacemaker implanta-
tion in 3 (2.5%).
New or increased ventricular arrhythmias. All seven pa-
tients with new or increased ventricular arrhythmias had
nonsustained ventricular tachycardia that was new or increased
after initiation of sotalol (Tables 2 and 3). Of these seven
patients, two had nonsustained torsade de pointes that was
asymptomatic and nocturnal in both. One patient, a 78-year
old woman with normal left ventricular function, left ventric-
ular hypertrophy and a pacemaker for complete heart block,
had undergone aortic valve replacement. She developed ven-
Table 2. Distribution of Significant Arrhythmia Complications
Type
No. (%) of
Patients
New or increased VA only 1 (0.8%)
Significant bradycardia only 13 (10.8%)
Excessively prolonged QTc only 2 (1.7%)
Concomitant complications 9 (7.5%)
Bradycardia1prolonged QTc 3 (2.5%)
New or increased VA1prolonged QTc 2 (1.7%)
New or increased VA1bradycardia 3 (2.5%)
New or increased VA1bradycardia1QTc 1 (0.8%)
Total 25 (20.8%)
Total new or increased VA 7 (5.8%)
Nonsustained VT 7 (5.8%)
Torsade de pointes 2 (1.7%)
Increased ventricular ectopic beats 2 (1.7%)
Treatment required 7 (5.8%)
Sotalol discontinuation 3 (2.5%)
Dose reduction 3 (2.5%)
Potassium repletion 1 (0.8%)
Permanent pacemaker implantation 1 (0.8%)
Total significant bradycardia 20 (16.7%)
HR ,40 beats/min 14 (11.7%)
Pause .3.0 s 5 (4.2%)
3rd-degree AVB 1 (0.8%)
Treatment required 18 (15.0%)
Permanent pacemaker implantation 3 (2.5%)
Dose reduction 16 (13.3%)
Total excessively prolonged QTc 8 (6.7%)
AVB 5 atrioventricular block; HR 5 heart rate; QTc 5 corrected QT
interval; VA 5 ventricular arrhythmias; VT 5 ventricular tachycardia.
Table 3. Patients With New or Increased Ventricular Arrhythmias
Pt No. Age Gender New or Increased VA, Type (time)
Time to SAC (days)
Time to
Intervention
(days)
New or
Increased VA Bradycardia
QTc
Prolongation Earliest SAC
1 79 M NSVT 12 beats (2:30 AM) 1.5 — 1.5 1.5 2
2 74 M PM-NSVT, TdP 10 beats (12:47 AM) 4 0.5 — 0.5 3
3 69 M NSVT 15 beats, increased PVCs 3.5 3 9 3 3
4 68 M NSVT 4 beats, increased PVCs 3 — — 3 3.5
5 46 M NSVT 12 beats 1 — — 1 2
6 75 M NSVT 5 beats, increased PVCs 1.5 1 — 1 3
7 78 F NSVT, TdP, decreased K (1:20 AM) 6 — 6 6 6
K 5 potassium; PM-NSVT 5 polymorphic nonsustained ventricular tachycardia; Pt 5 patient; PVCs 5 premature ventricular complexes; SAC 5 significant
arrhythmia complication; TdP 5 torsade de pointes; other abbreviations as in Tables 1 and 2.
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tricular bigeminy and 11-beat torsade de pointes occurring on
day 6 after sotalol initiation. This event, which occurred during
sotalol therapy of 160 mg twice daily and a pacemaker
programmed to a lower rate limit of 60 beats/min, was associ-
ated with mild hypokalemia (K1 3.4 mmol/liter) during di-
uretic therapy and resolved on repletion of potassium. The
baseline QT interval was 320 ms (QTc 391 ms) and had
increased to 484 ms (QTc 548 ms) at the time of the torsade de
pointes. The second patient was a 74-year old man with
coronary artery disease, moderate left ventricular dysfunction,
ventricular tachycardia and an implantable cardioverter-
defibrillator (ICD) with antibradycardic pacing programmed
to VVI at 40 beats/min. He had received sotalol (160 mg twice
daily) for 3 days, which was decreased to 120 mg twice daily
after conversion of atrial fibrillation to sinus bradycardia
during an ICD shock delivered for assessment of ventricular
defibrillation safety margin. This patient developed bradycardia-
associated nonsustained torsade de pointes on day 4 after
sotalol initiation, the night after conversion to sinus rhythm,
during VVI pacing at the lower rate limit, and was treated with
a further reduction in sotalol dosage. His baseline QT and QTc
intervals were 412 and 435 ms, respectively, increasing to 472
and 443 ms with sotalol, respectively. Three of seven cases of
new or increased ventricular arrhythmias occurred in the early
morning hours between midnight and 2:30 AM. Two patients
had an increase in ventricular ectopic frequency detected with
monitoring that resulted in discontinuation of sotalol in one
patient. The other patient underwent a reduction in dosage for
increased ventricular ectopic beats, nonsustained ventricular
tachycardia and concomitant significant bradycardia. All seven
patients with new or increased ventricular arrhythmias under-
went a change in treatment during the hospital period: Three
patients were treated with reduction in dosage, three with
discontinuation of sotalol, one with repletion of potassium and
one with implantation of a permanent pacemaker.
Time to detection of significant arrhythmia complications.
The mean time to the earliest detection of significant arrhyth-
mia complications was 2.1 6 2.5 days (range 0.5 to 12) after
sotalol initiation (Fig. 1). The time to detection of new or
increased ventricular arrhythmias was 3.2 6 1.8 days (range 1
to 6), significant bradycardia 1.9 6 1.8 days (range 0.5 to 8) and
excessively prolonged QTc interval 4.4 6 4.2 days (range 0.5 to
12). The time monitored in the hospital during sotalol therapy
after its initiation was 5.9 6 6.8 days (range 1 to 33) in the total
group. Criteria for any significant arrhythmia complication, as
defined in the present study, were met in 17 and 22 of the 25
patients with complications within 2 and 3 days of hospital
admission, respectively. Except for the patient with torsade de
pointes occurring in the setting of hypokalemia, the earliest
significant arrhythmia complication detection was within 3 days
in all patients with new or increased ventricular arrhythmias.
Nocturnal (between 10 PM and 8 AM) significant bradycardia
was detected in 12 patients. Both episodes of torsade de
pointes occurred nocturnally.
Significant arrhythmia complications in patients without
underlying heart disease. Of the 24 patients without underly-
ing heart disease, 3 (12.5%) developed significant arrhythmia
complications. Two patients experienced bradycardia (minimal
rates 37 and 39 beats/min, respectively), prompting a decrease
in dosage in one patient. New or increased ventricular arrhyth-
mias (nonsustained ventricular tachycardia and increased ven-
tricular ectopic beats) were detected in one patient and led to
discontinuation of sotalol.
Predictors of significant arrhythmia complications. Uni-
variate and multivariate analyses showed that initial dosage
was not a significant determinant of the development of
significant complications (Table 4). In the total group, the
mean starting dose of sotalol was 192 mg/day (median dose
160, range 80 to 320). There were no significant differences in
initial or discharge doses between groups that did or did not
develop significant arrhythmia complications, although there
was a trend toward higher initial and lower discharge dosages
in patients who had developed significant arrhythmia compli-
cations. Baseline ECG intervals, including QT, QTc, JT or
corrected JT intervals, were not predictive of significant in-
hospital arrhythmia complications. Concomitant digoxin or
beta-adrenergic or calcium channel blocking agent (diltiazem
or verapamil) use also did not predict complications. Age,
creatinine clearance, ventricular function, previous history of
ventricular arrhythmias and baseline rhythm also did not
predict significant arrhythmia complications.
The absence of a permanent pacemaker before sotalol
initiation was the only variable identified as a significant
predictor of arrhythmia complications by the p , 0.05 signif-
Figure 1. Time to detection of significant arrhythmia
complications (SAC) after initiation of sotalol. The
mean time to the earliest detection of clinically signifi-
cant arrhythmia complications was 2.0 6 1.9 days. The
time to detection of new or increased ventricular ar-
rhythmias was 2.9 6 1.8 days, significant bradycardia
2.0 6 1.8 days and excessively prolonged QTc intervals
3.3 6 3.1 days. The time monitored in the hospital
during sotalol therapy after its initiation was 4.7 6 4.0
days in the total group.
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icance criterion. The statistical significance of this variable was
robust to adjustments for marginal predictors (p , 0.05 to p ,
0.20). Similarly, adjustment for the absence of a pacemaker did
not magnify the marginal effects of the other variables. These
same findings were achieved using stepwise selection methods.
Only 2 (6.5%) of 31 patients with a permanent pacemaker
developed significant arrhythmia complications compared with
23 (25.8%) of 89 without a pacemaker (p 5 0.022). One patient
with a pacemaker developed torsade de pointes associated with
hypokalemia, and another had excessive prolongation of the
QTc interval.
No significant predictors for new or increased ventricular
arrhythmias could be identified.
Long-term follow-up. One hundred four patients were
discharged from the hospital with sotalol therapy (mean dose
at hospital discharge 227 6 77 mg/day). Three of the 120
patients with initial sotalol therapy died after a mean follow-up
period of 7.8 months. All died of noncardiac causes (massive
cerebrovascular accident, pneumonia, esophageal cancer). No
patients with significant arrhythmia complications that devel-
oped in the hospital died during follow-up. Pacemakers were
implanted in four patients after discharge, one in a patient who
had experienced significant in-hospital bradycardia and QTc
interval prolongation. Of the 20 patients who experienced
significant in-hospital arrhythmia complications and were dis-
charged with sotalol, the drug was subsequently discontinued
in 9, a pacemaker was implanted in 1 (who had experienced
significant in-hospital bradycardia and QTc interval prolonga-
tion), and increased ectopic activity was noted in 1 (1 month
later). Of the 84 patients discharged with sotalol who had not
experienced significant in-hospital arrhythmia complications,
pacemakers were implanted in 3, and new or increased ven-
tricular arrhythmias were noted in 3 (2 with increased ectopic
activity after initiation of sotalol, 2 with incessant or increased
supraventricular tachycardia 2 months later). Sotalol was dis-
continued in 44 patients (1 because of QT interval prolonga-
tion, 2 because of new or increased ventricular arrhythmias and
the remainder because of side effects or inefficacy).
Discussion
The current study shows that the incidence of significant
arrhythmia complications during initiation of sotalol therapy
appears significant enough to warrant inpatient initiation.
Bradycardia is the most frequent complication. Baseline pa-
tient characteristics or ECG variables could not be used to
predict a low risk group, although patients with pacemakers
were at lower risk for complications.
Previous studies of antiarrhythmic drug safety. Random-
ized studies of antiarrhythmic agents used for ventricular
arrhythmias have demonstrated that the empiric use of class I
antiarrhythmic drugs can be associated with the possibility of
worsened survival (17–19). Although a potential exception is
amiodarone, an antiarrhythmic agent with class III potassium
channel blocking activity (20–23), the recent premature termi-
nation of the Survival With Oral D-Sotalol (SWORD) trial
(24), a study for ventricular arrhythmias using the class III drug
d-sotalol, highlights the need for continued caution, even with
this group of antiarrhythmic agents.
Similar caution has been engendered by recent studies of
antiarrhythmic drug use for atrial fibrillation. A meta-analysis
of quinidine use for atrial arrhythmias (25) showed a threefold
increase in overall mortality in patients treated with quinidine
compared with placebo (2.9% vs. 0.8%), although the numbers
of cardiovascular deaths were small. Although not random-
ized, antiarrhythmic drug use in the Stroke Prevention in
Atrial Fibrillation (SPAF) trial (26) was associated with an
increase in cardiac and arrhythmic death in patients with a
history of congestive heart failure. These concerns have led to
the initiation of a multicenter trial of ventricular rate control
versus maintenance of sinus rhythm in patients with atrial
fibrillation (the Atrial Fibrillation Follow-Up Investigation Of
Rhythm Management [AFFIRM]).
Previous studies on sotalol. A pooled analysis of 1,288
patients enrolled in premarketing controlled trials using sotalol
(7) showed that symptomatic bradyarrhythmias occurred in
111 patients, with 2.7% discontinuing because of bradycardia.
New or increased ventricular arrhythmias occurred in 4.3%,
with 2% classified as minor and 2% as severe (1.9% torsade de
pointes). Other studies (1–8) have shown the risk of proar-
Table 4. Sotalol Dosage, Baseline Electrocardiographic Variables
and Concomitant Medications
No SAC SAC p Value
Sotalol dosage (mg/day)
Initial dose 187.8 6 54.4 208.0 6 69.3 0.122
Median 160 160
Discharge dose 232.5 6 78.7 206.0 6 67.8 0.17
Median 160 160
Baseline ECG variables
HR (beats/min) 79.1 6 19.4 79.3 6 23.3 0.963
SR rate 69.8 6 12.4 68.8 6 17.8 0.835
AF rate 87.1 6 20.9 86.8 6 24.4 0.967
PR interval (ms) 177.9 6 36.4 175.8 6 47.5 0.872
QT interval (ms) 398.8 6 65.8 394.1 6 61.4 0.749
QTc interval (ms) 454.4 6 55.4 439.9 6 38.3 0.220
QRS Interval (ms) 117.2 6 37.5 116.5 6 27.6 0.931
Concomitant medications
Digoxin
2 67 19 0.589
1 28 6
Beta-blockers
2 98 23 0.191
1 2 2
Verapamil or diltiazem
2 91 25 0.579
1 4 0
Total
2 61 17 0.724
1 34 8
Data presented are mean value 6 SD, median or number of patients. AF 5
atrial fibrillation; SR 5 sinus rhythm; 1 5 yes; 2 5 no; other abbreviations as
in Tables 2 and 3.
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rhythmia from sotalol to be comparable to that of class IA
antiarrhythmic drugs, with a reported range of 1% to 8%.
Sotalol causes a concentration-dependent lengthening of
the QT interval (27,28). The drug increases action potential
duration and refractory periods in cardiac tissue, most likely by
a reduction in the delayed rectifier potassium current (IK), with
selective blockade of the rapid component (IKr) (29–31). A
small reduction in the inward rectifier potassium current (IK1)
and blockade of the transient outward potassium current (Ito)
in Purkinje fibers may also contribute to its action (32).
Excessive prolongation of the QT interval by sotalol has been
associated with the risk for significant arrhythmia proarrhyth-
mia, particularly from torsade de pointes, in some studies (6,7),
although this has not been uniformly reported (33).
Sotalol also has substantial beta-adrenergic blocking effects,
with a potency similar to that of propranolol (34,35). The
effects of sotalol on repolarization exhibit reverse use depen-
dence, with a smaller effect at rapid rates and a more promi-
nent effect at slow heart rates (14,15). This property may not
only limit its effectiveness as an antiarrhythmic drug at rapid
tachycardia rates, but could also produce more pronounced
QT interval prolongation and risk for torsade de pointes
during bradycardia. Bradyarrhythmias may not be readily or
promptly detected during outpatient management because
minimal bradycardia rates usually occur nocturnally during
sleep.
However, because of the dose-dependent effects of sotalol,
outpatient initiation has been performed in some patients,
beginning with low doses. Nevertheless, torsade de pointes has
been reported to occur early after initiation in patients treated
for atrial fibrillation, after restoration of sinus rhythm or after
an increase in dosage (2,7). Kehoe et al. (6) reported that
proarrhythmia occurred in 31 (6.4%) of 481 patients treated
for sustained ventricular arrhythmias. These events occurred
within the acute loading phase of therapy in 23 patients (74%).
Of the 15 patients who experienced torsade de pointes, all but
2 experienced it within 8 days of initiating or increasing sotalol
dosage.
The current study. Incidence of complications. Approxi-
mately one in five patients initiated sotalol therapy appeared to
benefit from inpatient monitoring and surveillance. Most com-
plications consisted of significant bradyarrhythmias; however,
asymptomatic nocturnal torsade de pointes was detected.
Criteria for significant arrhythmia complications. The cri-
teria for serious complications in the present study were
selected to detect significant arrhythmias or QTc prolongation
that might require prompt intervention, including dosage
adjustments, discontinuation of the drug or pacing. Such
expeditious detection and intervention might be difficult to
achieve during outpatient management. Potentially serious
concomitant QTc interval prolongation and bradycardia did
occur in a majority of the patients with new or increased
ventricular arrhythmias, which may have facilitated earlier
intervention. A lesser degree of bradycardia and QTc interval
prolongation also occurred. Hypotension, congestive heart
failure, bronchospasm or other potential side effects of sotalol
occurred as well but were not considered immediately life
threatening.
Symptoms were not considered necessary for inclusion as a
serious complication because the primary purpose of the
present study was to determine the need for in-hospital
monitoring. Symptomatic arrhythmias, although potentially
serious, would generally prompt patients to call or return for
medical attention. However, asymptomatic arrhythmias may
not prompt medical attention early enough to avoid serious
arrhythmias in an outpatient, yet could still be a harbinger of
impending serious complications. In the current study, half of
the patients with significant bradycardia and both patients with
torsade de pointes had this event recorded during nocturnal
hours. Patients may also be at an especially high risk for
proarrhythmia as inpatients or outpatients, despite being
asymptomatic, if they pharmacologically convert to sinus
rhythm on sotalol after long-standing atrial fibrillation (2) and
have significant bradycardia afterward.
Duration of hospital stay required to detect complications.
The time course of occurrence of significant arrhythmias is
important in decisions regarding inpatient or outpatient initi-
ation of antiarrhythmic drug therapy. Criteria for any signifi-
cant arrhythmia complication as defined in the present study
was met within 3 days in all but three patients, supporting a
significant yield of hospital monitoring with a 3-day hospital
period. All patients with new or increased ventricular arrhyth-
mias met a criterion for significant arrhythmia complication
within 3 days, except for the one patient with torsade de
pointes who had hypokalemia.
Prediction of safety for outpatient initiation. Baseline
ECG intervals, including heart rate and QT intervals, and
sotalol dosage were not significantly predictive of the develop-
ment of significant arrhythmia complications and therefore
could not be used to determine in whom sotalol therapy might
be safely started on an outpatient basis. These findings are in
contrast to a previous study (7) in which patients who devel-
oped severe proarrhythmia had longer mean baseline QT and
QTc intervals. Our findings are consistent with those of Kehoe
et al. (6) who reported that proarrhythmia was not related to
sotalol dose, baseline heart rate and QT intervals. Our study
also showed that the paroxysmal or chronic nature of atrial
fibrillation was not predictive of complications. In addition, the
absence of heart disease did not identify a low risk group for
significant arrhythmia complications, although torsade de
pointes did not occur in this group. However, the small sample
size of this subgroup limits generalization of this observation.
The only significant predictor of significant arrhythmia
complications was the presence or absence of a permanent
pacemaker. Pacemakers would be expected to prevent the
significant bradyarrhythmias that could be induced by sotalol
therapy. However, the two cases of torsade de pointes occurred
in one patient with a pacemaker and one with an ICD. These
cases indicate that pacing may not be entirely protective of
proarrhythmia, particularly at low pacing rates. Patients who
are not protected from bradycardia with a pacemaker may
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benefit the most from inpatient monitoring, but hospital
admission may still be advisable for some, if not all, patients
with pacemakers. In addition, careful avoidance of hypokale-
mia and programming of backup pacing rates to higher rates
might be prudent if sotalol is being initiated.
Long-term follow-up did not reveal deaths from late proar-
rhythmia. This finding may reflect either the limitations from
sample size or the effect of risk stratification and interventions,
such as dosage reductions, drug discontinuation or pacing, that
were prompted during inpatient monitoring or subsequent
outpatient surveillance. Several patients did require pace-
maker implantation after discharge, and two patients had
subsequent proarrhythmia detected, although torsade de
pointes did not occur.
Limitations. The present study was a retrospective review,
with significant arrhythmia complications detected by chart
review. The criteria for significant complications were retro-
spectively defined. The determination of new or increased
ventricular arrhythmias was dependent on clinician assessment
rather than specific numeric criteria. The time to detection of
significant arrhythmia complications most likely underesti-
mates the time to clinical recognition of these complications,
underscoring the need for adequate duration of monitoring
and the need for prospective assessment of the yield of
inpatient monitoring or safety of outpatient drug initiation if
the latter is pursued. One potential difference in the manner in
which sotalol therapy may be initiated in outpatients is in the
starting dose or rate of dosage escalation. Outpatient manage-
ment may include initiation at lower doses with slower dose
titration. However, the median starting dose in the current
inpatient study was 160 mg/day, and our conclusions do not
appear to be affected by dose-dependent effects.
Conclusions. A significant incidence (20.8%) of significant
arrhythmia complications occurred during sotalol loading that
could be detected by in-hospital monitoring. These events
triggered changes in therapy in 17.5% of patients with initia-
tion of sotalol. The most frequent serious complication de-
tected was significant bradycardia (16.7%). The incidence of
new or increased ventricular arrhythmias was 5.8%, with a
1.77% incidence of torsade de pointes. When present, brady-
cardia and torsade de pointes occurred frequently during
nocturnal hours. Most significant arrhythmia complications
were detected within the first 3 days of monitoring. Baseline
ECG intervals, including QT intervals, or rhythm were not
predictive of these complications. Although the absence of
overt heart disease did not identify a low risk subgroup for the
significant arrhythmia complications of bradycardia and non-
sustained ventricular tachycardia, torsade de pointes did not
occur in this group. However, generalization of this observa-
tion should be limited by the small sample size of this
subgroup. The absence of a permanent pacemaker before
sotalol initiation was the only significant predictor of the
development of significant arrhythmia complications.
Recommendations. Patients who are not protected from
bradycardia with a pacemaker should be admitted to the
hospital for inpatient monitoring during sotalol initiation.
However, even in patients with a pacemaker, careful avoidance
of hypokalemia, programming of backup pacing rates to higher
rates and hospital admission for some, if not all, of these
patients as well may be prudent if sotalol is being initiated. The
yield of hospital monitoring after initiation of sotalol suggests
that at least 72 h of observation may be beneficial.
We are grateful for the helpful reviews of Eric J. Topol, MD and Clifford V.
Harding III, MD, PhD, as well as the secretarial assistance of Rosemarie Capone
and Shelly White.
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